The Clinical Effect and Mechanism of Kechuan Guben Pills for Blood Stasis Syndrome of COPD in Stable Stage

Xun-qing Ni¹, Qin-shuai Ni², Wen-cai Song¹, Feng Gao^3, and Xin-wei Zhang^4,

¹Department of Respiratory and Critical Care Medicine, Linyi TCM Hospital, Linyi 276003, China

²Institute of Integrate Medicine, Qingdao University Medical College, Qingdao 266021, China

³Department of Neurosurgery, Jinan Jiyang District People’s Hospital, Jinan 251400, China

⁴Department of Medical Imaging, Linyi Municipal People's Hospital, Linyi 276003, China

Cite this paper:
Xun-qing Ni, Qin-shuai Ni, Wen-cai Song, Feng Gao and Xin-wei Zhang. The Clinical Effect and Mechanism of Kechuan Guben Pills for Blood Stasis Syndrome of COPD in Stable Stage. American Journal of Medical Sciences and Medicine. 2024; 12(4):80-84. doi: 10.12691/ajmsm-12-4-1

Abstract

Objective: To observe the therapeutic efficacy and possible mechanism of Kechuan Guben Pills (KGP) in patients with blood stasis syndrome of COPD in stable stage. Methods: All patients diagnosed with blood stasis syndrome of COPD in stable stage hospitalized in Department of Respiratory and Critical Care Medicine, Linyi TCM Hospital from June 2021 to January 2023, were selected and randomly divided into control group received Budesonide 2 puffs, twice a day and treatment group given KGP on the basis of control group, 9 g, twice a day for six months. The traditional Chinese medicine (TCM) syndrome scores of patients were collected according to TCM Syndrome Diagnosis Criteria of Chronic Obstructive Pulmonary Diseaseand and the serum levels of interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), high-sensitivity C-reactive protein (hs-CRP), transforming growth factor-β (TGF-β) and vascular endothelial growth factor (VEGF) were determined by immunofluorescence assay and latex enhanced immunoscattering turbidimetric assay. Results: The taotal effective rate of patients in the treatment group (96.97%) was significantly higher than that in the control group (82.86%), P < 0.05. The TCM syndrome scores of patients in the treatment group showed significant improvement compared to the control group (P < 0.01). The serum levels of IL-6, TNF-α, hs-CRP, TGF-β and VEGF in the treatment group showed significantly better than those in the treatment group (P < 0.01). Conclusion: KGP could significantly improve TCM symptoms of patients with blood stasis syndrome of COPD in stable stage by inhibiting the expressions of inflammatory factors and regulating the collagen fiber deposition related factors in the extracellular matrix.

Keywords:
kechuan guben pills COPD blood stasis syndrome TCM syndrome score inflammatory factor

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Ruvuna L, Sood A. Epidemiology of chronic obstructive pulmonary disease. Clin Chest Med, 2020, 41(3): 315-327.
[2]	Pinezich MR, Tamargo MA, Fleischer S, et al. Pathological remodeling of distal lung matrix in end-stage cystic fibrosis patients. J Cyst Fibros, 2022, 21(6): 1027-1035.
[3]	Albertson TE, Bowman WS, Harper RW, et al. Evidence-based review of data on the combination inhaler umeclidinium/vilanterol in patients with COPD. Int J Chronic Obst, 2019, 14(14): 1251-1265.
[4]	Qiu J, Zhou JP, Gao CD, et al. Clinical observation of Wuzishen medicine decoction in treating the syndrome of deficiency of lung and spleen and internal accumulation of turbid phlegm. Progress in Modern Biomedicine, 201, 21(2): 311-315.
[5]	Yang Y. Treatment of chronic obstructive pulmonary disease with traditional Chinese medicine based on collateral-disease theory. Herald Med, 201, 40(9): 1221-1224.
[6]	Chen Y, Pan WQ. Treatment of 37 cases of COPD with deficiency of lung and kidney in stable stage by Yiqi Bushen Huoxue decoction. Hunan J TCM, 2020, 36(8): 43-44.
[7]	Group of Chronic obstructive pulmonary Disease, Respiratory Society of Chinese Medical Association, Working Committee of Chronic obstructive pulmonary Disease, Respiratory Society of Chinese Medical Association. Guidelines for diagnosis and treatment of chronic obstructive pulmonary disease (COPD). Chin J Tuberc Respir Dis, 2021, 44(3): 170-205.
[8]	Lung Diseases Professional Committee, Internal Medicine Branch, China Association of Traditional Chinese Medicine. Clinical diagnosis of chronic obstructive pulmonary disease: a review. J TCM, 2012, 53(2): 177-178.
[9]	Zheng XY. Chinese medicine new Drug clinical research guideline. China Medical Science and Technology Press, 2002.
[10]	Brandsma CA, van den Berge M, Hackett TL, et al. Recent advances in chronic obstructive pulmonary disease pathogenesis: from disease mechanisms to precision medicine. J Pathol, 2020, 250(5): 624-635.
[11]	Cheng L, Cai WR. CAI Wanru's clinical experience in treating chronic obstructive pulmonary disease (COPD) with airway mucus hypersecretion. J Zhejiang Univer TCM, 2020, 43(10): 1173-1175.
[12]	Yin ZX, Liu KQ, Chen J, et al. Clinical study of Bushen Xuanfei Prescription in treatment of chronic obstructive pulmonary disease in remission stage. Modern Medicine and Health, 2022, 38(8): 1270-1274.
[13]	Dawson RE, Jenkins BJ, Saad MI. IL-6 family cytokines in respiratory health and disease. Cytokine, 2021, 143: 155520.
[14]	Kubysheva N, Boldina M, Eliseeva T, et al. Relationship of serum levels of IL-17, IL-18, TNF-α, and lung function parameters in patients with COPD, asthma-COPD overlap, and bronchial asthma. Mediat Inflamm, 2020, 2020(4): 4652898-908.
[15]	Nolte MA, Margadant C. Controlling immunity and inflammation through integrin-dependent regulation of TGF-β. Trends Cell Biol, 2020, 30(1): 49-59.
[16]	Yang D, Wang L, Jiang P, et al. Correlation between hs-CRP, IL-6, IL-10, ET-1, and chronic obstructive pulmonary disease combined with pulmonary hypertension. J Healthc Eng, 2022, 2022: 3247807.
[17]	Ding Q, Sun S, Zhang Y, et al. Serum IL-8 and VEGFA are two promising diagnostic biomarkers of asthma-COPD overlap syndrome. Int J Chronic Obstr, 2020, 15: 357-365.
[18]	Hu YL, Cheng XM, Liu SY, et al. Study on mechanism of Radix Astragali-Atractylodes macrocephala in treatment of chronic obstructive pulmonary disease by combining with transcriptome and network pharmacology. Chin J Integr Tradit West Med, 2020, 40(10): 1196-1201.
[19]	Han XX, Zhao D, Liu XF, et al. Study on the mechanism of Radix Astragali seu Hedysari-Fructus Perillae combination in the treatment of chronic obstructive pulmonary disease based on network pharmacology and molecular docking. World Science and Technology-Modernization of TCM, 2021, 23(9): 162-174.
[20]	Tian FN, Yuan F, Xu N. Effects of Astragalus injection on expression of CRP, IL-6 and TNF-α in different preeclampsia model mice. J Clin Exp Med, 2020, 22(19): 2378-2383.
[21]	Zhou T, Zhou X, Wang XR. Mechanism of action of Panax ginseng-Poria cocos in treatment of chronic obstructive pulmonary disease: A study based on network pharmacology and molecular docking. Hunan J TCM, 2022, 38(5): 139-146.
[22]	Liu Y, Dong HR, Tian YG, et al. Effects of ginseng and tangerine peel on chronic obstructive pulmonary disease. World Science and Technology-Modernization of TCM, 2022, 24(6): 2264-2276.
[23]	Zhang WJ, Han DW, Li Y. Advances in chemical compositions and pharmacological effects of Alismatis rhizoma. Acta Chin Med Pharmacol, 2021, 49(12): 98-102.
[24]	An YX, Zhang XJ, Wang Z, et al. Effect of icariin on rats with pulmonary fibrosis and its mechanism. J Anhui Med Univer, 2020, 55(12): 1840-1844.
[25]	Zang H, Zhang HF, Xu Q, et al. Chemical constituents and pharmacological actions of Gekko gecko Linnaeus. J Jilin TCM, 2016, 36(9): 919-921.
[26]	Zhang Y, Yang J, Wang Q. Study on the application of Cicada exuviae, Digilosaurus and Bombyx rigidus in chronic airway diseases. Hunan J TCM, 2019, 35(8): 155-157.
[27]	Li J, Huo XY, Chen BQ, et al. Efficacy of Salvia miltiorrhiza injection combined with moxifloxacin in the treatment of elderly patients with acute onset of chronic obstructive pulmonary disease. Progress in Modern Biomedicine, 2019, 19(13): 2502-2505.